Literature DB >> 26888946

Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences.

László Gulácsi1, Fanni Rencz2, Gyula Poór3, Zoltán Szekanecz4, Valentin Brodszky1, Petra Baji1, Márta Péntek5.   

Abstract

Entities:  

Keywords:  Ankylosing Spondylitis; DMARDs (biologic); Health services research; Psoriatic Arthritis; Rheumatoid Arthritis

Mesh：

Year:  2016        PMID： 26888946     DOI： 10.1136/annrheumdis-2015-208741

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.

Authors:  László Gulácsi; Valentin Brodszky; Petra Baji; Fanni Rencz; Márta Péntek
Journal:  Adv Ther       Date:  2017-04-10       Impact factor: 3.845

2.  Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability.

Authors:  Zsombor Zrubka; Márta Péntek; Lea Mhanna; Teebah Abu-Zahra; Mohamed Mahdi-Abid; Meriem Fgaier; Faris El-Dahiyat; Hana Al-Abdulkarim; Michael Drummond; László Gulácsi
Journal:  Pharmacoeconomics       Date:  2022-05-17       Impact factor: 4.558

3.  Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data.

Authors:  Valentin Brodszky; Anikó Bíró; Zoltán Szekanecz; Boglárka Soós; Petra Baji; Fanni Rencz; László Tóthfalusi; László Gulácsi; Márta Péntek
Journal:  Clinicoecon Outcomes Res       Date:  2017-02-15

4.  Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.

Authors:  Petra Baji; László Gulácsi; Valentin Brodszky; Zsuzsanna Végh; Silvio Danese; Peter M Irving; Laurent Peyrin-Biroulet; Stefan Schreiber; Fanni Rencz; Péter L Lakatos; Márta Péntek
Journal:  United European Gastroenterol J       Date:  2017-05-08       Impact factor: 4.623

5.  Access to biologicals in Crohn's disease in ten European countries.

Authors:  Márta Péntek; Peter L Lakatos; Talitha Oorsprong; László Gulácsi; Milena Pavlova; Wim Groot; Fanni Rencz; Valentin Brodszky; Petra Baji
Journal:  World J Gastroenterol       Date:  2017-09-14       Impact factor: 5.742

6.  Costs of drugs for treatment of rheumatic diseases.

Authors:  Rene Westhovens; Lieven Annemans
Journal:  RMD Open       Date:  2016-09-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.